Have a personal or library account? Click to login

FDG PET-CT as an important diagnostic tool and prognostic marker in suspected recurrent cervical carcinoma after radiotherapy: comparison with MRI

Radiology and Oncology
Volume 56 (2022): Issue 4 (December 2022)
By:
Open Access
|Nov 2022

References

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin 2021; 71: 209-49. doi: 10.3322/caac.21669
    Open DOISearch in Google ScholarBack to article
  2. Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri. Int J Gynaecol Obstet 2018; 143(Suppl 2): S22-36. doi: 10.1002/ijgo.13865
    Open DOISearch in Google ScholarBack to article
  3. Quinn MA, Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, et al. Carcinoma of the cervix uteri. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 2006; 95(Suppl 1): S43-103. doi: 10.1016/S0020-7292(06)60030-1
    Open DOISearch in Google ScholarBack to article
  4. Thomas GM, Dembo AJ, Myhr T, Black B, Pringle JF, Rawlings G. Long-term results of concurrent radiation and chemotherapy for carcinoma of the cervix recurrent after surgery. Int J Gynecol Cancer 1993; 3: 193-8. doi: 10.1046/j.1525-1438.1993.03040193.x
    Open DOISearch in Google ScholarBack to article
  5. Gandy N, Arshad MA, Park WE, Rockall AG, Barwick TD. FDG-PET Imaging in cervical cancer. Semin Nucl Med 2019; 49: 461-70. doi: 10.1053/j.semnu-clmed.2019.06.007.
    Open DOISearch in Google ScholarBack to article
  6. Patel-Lippmann K, Robbins JB, Barroilhet L, Anderson B, Sadowski EA, Boyum J. MR imaging of cervical cancer. Magn Reson Imaging Clin N Am 2017; 25: 635-49. doi: 10.1016/j.mric.2017.03.007
    Open DOISearch in Google ScholarBack to article
  7. Palaniswamy SS, Borde CR, Subramanyam P. 18F-FDG PET/CT in the evaluation of cancer cervix: where do we stand today? Nucl Med Commun 2018; 39: 583-92. doi: 10.1097/MNM.0000000000000851
    Open DOISearch in Google ScholarBack to article
  8. Vinh-Hung V, Bourgain C, Vlastos G, Cserni G, De Ridder M, Storme G et al. Prognostic value of histopathology and trends in cervical cancer: a SEER population study. BMC Cancer 2007; 7: 164. doi:10.1186/1471-2407-7-164
    Open DOISearch in Google ScholarBack to article
  9. Cancer.Net. Cervical Cancer: Statistics. [Internet]. American Society of Clinical Oncology (ASCO); c2005-21. [cited 2021 Aug 17]. Available from: https://www.cancer.net/cancer-types/cervical-cancer/statistics
    Search in Google ScholarBack to article
  10. Kidd EA, Siegel BA, Dehdashti F, Grigsby PW. The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer 2007; 110: 1738-44. doi: 10.1002/cncr.22974
    Open DOISearch in Google ScholarBack to article
  11. Kidd EA, Siegel BA, Dehdashti F, Rader JS, Mutch DG, Powell MA, et al. Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis. J Clin Oncol 2010; 28: 2108-13. doi: 10.1200/JCO.2009.25.4151
    Open DOISearch in Google ScholarBack to article
  12. Yen TC, See LC, Lai CH, Tsai CS, Chao A, Hsueh S, et al. Standardized uptake value in para-aortic lymph nodes is a significant prognostic factor in patients with primary advanced squamous cervical cancer. Eur J Nucl Med Mol Imaging 2008; 35: 493-501. doi: 10.1007/s00259-007-0612-1
    Open DOISearch in Google ScholarBack to article
  13. Han S, Kim H, Kim YJ, Suh CH, Woo S. Prognostic value of volume-based metabolic parameters of 18F-FDG PET/CT in uterine cervical cancer: a systematic review and meta-analysis. AJR Am J Roentgenol 2018; 211: 1112-21. doi: 10.2214/AJR.18.19734
    Open DOISearch in Google ScholarBack to article
  14. Miccò M, Vargas HA, Burger IA, Kollmeier MA, Goldman DA, Park KJ, et al. Combined pre-treatment MRI and 18F-FDG PET/CT parameters as prognostic biomarkers in patients with cervical cancer. Eur J Radiol 2014; 83: 1169-76. doi: 10.1016/j.ejrad.2014.03.024
    Open DOISearch in Google ScholarBack to article
  15. Ho JC, Allen PK, Bhosale PR, Rauch GM, Fuller CD, Mohamed AS, et al. Diffusion-weighted magnetic resonance imaging as a predictor of outcome in cervical cancer after chemoradiation. Int J Radiat Oncol Biol Phys 2017; 97: 546-53. doi: 10.1016/j.ijrobp.2016.11.015
    Open DOISearch in Google ScholarBack to article
  16. Tavassoéli FA, Devilee P. IARC WHO classification of tumours, pathology and genetics tumours of the breast and female genital organs. Vol 4. 3rd edition. Lyon: IARC publications; 2003.
    Search in Google ScholarBack to article
  17. Kurman RJ, Hedrick-Ellenson L, Ronnett BM. Blaustein’s pathology of the female genital tract. 6th edition. New York: Springer; 2011.
    Search in Google ScholarBack to article
  18. Meads C, Davenport C, Małysiak S, Kowalska M, Zapalska A, Guest P, et al. Evaluating PET-CT in the detection and management of recurrent cervical cancer: systematic reviews of diagnostic accuracy and subjective elicitation. BJOG 2014; 121: 398-407. doi: 10.1111/1471-0528.12460
    Open DOISearch in Google ScholarBack to article
  19. Chu Y, Zheng A, Wang F, Lin W, Yang X, Han L, et al. Diagnostic value of 18F-FDG-PET or PET-CT in recurrent cervical cancer: a systematic review and meta-analysis. Nucl Med Commun 2014; 35: 144-50. doi: 10.1097/MNM.0000000000000026
    Open DOISearch in Google ScholarBack to article
  20. Pallardy A, Bodet-Milin C, Oudoux A, Campion L, Bourbouloux E, Sagan C, et al. Clinical and survival impact of FDG PET in patients with suspicion of recurrent cervical carcinoma. Eur J Nucl Med Mol Imaging 2010; 37: 1270-8. doi: 10.1007/s00259-010-1417-1
    Open DOISearch in Google ScholarBack to article
  21. Bjurberg M, Brun E. Clinical impact of 2-deoxy-2-[18F] fluoro-D-glucose (FDG)-positron emission tomography (PET) on treatment choice in recurrent cancer of the cervix uteri. Int J Gynecol Cancer 2013; 23: 1642-6. doi: 10.1097/IGC.0b013e3182a50537
    Open DOISearch in Google ScholarBack to article
  22. Lai CH, Huang KG, See LC, Yen TC, Tsai CS, Chang TC, et al. Restaging of recurrent cervical carcinoma with dual-phase [18F] fluoro-2-deoxy-D-glucose positron emission tomography. Cancer 2004; 100: 544-52. doi: 10.1002/cncr.11928
    Open DOISearch in Google ScholarBack to article
  23. Yen TC, Lai CH, Ma SY, Huang KG, Huang HJ, Hong JH, et al. Comparative benefits and limitations of 18F-FDG PET and CT-MRI in documented or suspected recurrent cervical cancer. Eur J Nucl Med Mol Imaging 2006; 33: 1399-407. doi: 10.1007/s00259-006-0090-x
    Open DOISearch in Google ScholarBack to article
  24. Grigsby PW, Siegel BA, Dehdashti F, Rader J, Zoberi I. Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J Clin Oncol 2004; 22: 2167-71. doi: 10.1200/JCO.2004.09.035
    Open DOISearch in Google ScholarBack to article
  25. Schwarz JK, Siegel BA, Dehdashti F, Grigsby PW. Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma. JAMA 2007; 298: 2289-95. doi: 10.1001/jama.298.19.2289
    Open DOISearch in Google ScholarBack to article
  26. Kim YJ, Han S, Kim YS, Nam JH. Prognostic value of post-treatment 18F-fluorodeoxyglucose positron emission tomography in uterine cervical cancer patients treated with radiotherapy: a systematic review and meta-analysis. J Gynecol Oncol 2019; 30: e66. doi: 10.3802/jgo.2019.30.e66.
    Open DOISearch in Google ScholarBack to article
  27. Onal C, Guler OC, Reyhan M, Yapar AF. Long-term outcomes of cervical cancer patients with complete metabolic response after definitive chemoradiotherapy. J Gynecol Oncol 2021; 32: e74. doi: 10.1016/j.clon.2021.03.022
    Open DOISearch in Google ScholarBack to article
  28. Chung HH, Kim JW, Kang KW, Park NH, Song YS, Chung JK, et al. Predictive role of post-treatment [18F] FDG PET/CT in patients with uterine cervical cancer. Eur J Radiol 2012; 81: e817-e822. doi: 10.1016/j.ejrad.2012.02.015
    Open DOISearch in Google ScholarBack to article
DOI: https://doi.org/10.2478/raon-2022-0042 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 453 - 460
Submitted on: Apr 18, 2022
Accepted on: Sep 15, 2022
Published on: Nov 2, 2022
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
uterine cervical neoplasms,
recurrence,
PET-CT,
MRI,
progression-free survival,
sensitivity and specificity
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology,
Radiology

© 2022 Milica Stojiljkovic, Dragana Sobic Saranovic, Strahinja Odalovic, Marina Popovic, Jelena Petrovic, Nevena Rankovic, Milos Veljkovic, Vera Artiko, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution 4.0 License.

Previous articleVolume 56 (2022): Issue 4 (December 2022)Next article